MPWT
CLDX icon

MassMutual Private Wealth & Trust’s Celldex Therapeutics CLDX Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$670 Hold
18
– – ﹤0.01% 2238
2026
Q1 		$571 Buy
+18
New +$491 ﹤0.01% 2208

Other funds holding CLDX

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $418M AUM 68.45% 1-Year Est. Return
MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

MassMutual Private Wealth & Trust's CLDX Position: Q2 2026 in Review

MassMutual Private Wealth & Trust held its Celldex Therapeutics (CLDX) position steady in Q2 2026 at 18 shares worth $670. The position accounts for ﹤0.01% of the portfolio, ranked #2238.

MassMutual Private Wealth & Trust first reported a position in CLDX in Q1 2026 and has held it in 2 quarters since. 47 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • MassMutual Private Wealth & Trust held 18 shares of Celldex Therapeutics worth $670 as of Q2 2026.
  • MassMutual Private Wealth & Trust left its Celldex Therapeutics share count unchanged in Q2 2026.
  • Celldex Therapeutics made up ﹤0.01% of MassMutual Private Wealth & Trust's portfolio in Q2 2026, its #2238 holding.
  • MassMutual Private Wealth & Trust first reported a position in Celldex Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 47 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on MassMutual Private Wealth & Trust's 13F filing for Q2 2026, filed 2 Jul 2026.